REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise against tough leukemia
Disease control CompletedThis study tested a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 adults with a rare, aggressive leukemia called Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia in blast phase. The goal was to see if the drugs cou…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Stem cell transplant study seeks best way to prevent immune attack
Disease control CompletedThis study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New antibody drug tested in patients with relapsed blood cancers
Disease control CompletedThis early-stage trial tested the safety and best dose of flotetuzumab, an antibody drug, in 13 patients with advanced blood cancers that had come back or stopped responding to treatment. The drug works by blocking cancer cell growth. The main goal was to see what side effects oc…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC